Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 19, 2013

View Archived Issues

Pharmacological disruption of the Gram-negative bacteria protective capsule using a glycomimetic

Novel molecular classifier for predicting metastatic thymoma progression

Novel EGFR inhibitors discovered at Astellas Pharma

Novartis describes new antineoplastic agents

NMR reveals novel biomarkers of systemic inflammation

Phase II trial of Adcetris in combination with standard of care for frontline DLBCL commences

ADXS-HPV receives orphan drug designation for HPV-associated anal cancer

Chelsea Therapeutics submits additional information on Northera NDA

Institut Pasteur Korea and DNDi to focus on neglected diseases

Forest Laboratories and Almirall delay NDA filing for aclidinium/formoterol

Ultragenyx receives U.K. approval to conduct phase I/II UX-003 trial

MannKind reports data from two phase II diabetes studies of Afrezza

Amorfix Life Sciences provides update on ovarian cancer program

Researchers identify UBE2C as a potential target gene for melanoma

Theravance launches Vibativ for hospital-acquired and ventilator-associated bacterial pneumonia

GSK gains European approval for Tyverb-trastuzumab combination

Patient enrolled in brain tumor vaccine trial at Northwestern Memorial Hospital

Boehringer Ingelheim confirms full enrollment in phase III interferon-free HCV trials

TTP-399 demonstrates efficacy in phase II diabetes trial

Mologen provides update on product pipeline

FDA grants orphan drug status for Epizyme's EPZ-5676 in acute leukemia with MLL rearrangements

Jetrea approved for symptomatic vitreomacular adhesion in Canada

New kinase inhibitors described at Suzhou NeuPharma

Norgine's Dantrium shown to reduce fatal anesthetic reaction

Vernalis presents novel Chk1 inhibitors for cancer and autoimmune disorders

Prosonix completes all clinical procedures in phase II PSX-1002 study in COPD